Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia

Status unconfirmed · Phase 2

Conditions studied: Community Acquired Pneumonia

In brief

This study will compare the efficacy, safety and tolerability of EDP-420 versus another oral antibiotic in the treatment of community acquired pneumonia

Key facts

Study ID

NCT00270517

Run by

Enanta Pharmaceuticals, Inc

People needed

250

Starts

2005-12-01

Expected to finish

2007-07-01

Last updated by the study team

2006-09-19

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Recent respiratory illness with signs and symptoms and chest X-ray consistent with the diagnosis of community-acquired pneumonia.
• Suitable candidate for oral antibiotic therapy and able to swallow large capsules intact
• If female, must be non-lactating and at no risk for pregnancy

You may not qualify if…

• Other infections
• Other pulmonary diseases requirement multiple antibacterial medications or long duration of therapy
• History of hypersensitivity, allergic or adverse reactions to macrolide, ketolide, azalide or streptogramins
• Evidence of uncontrolled clinically significant disease, malignancy, or other abnormality
• Requirement of parenteral antimicrobial therapy for treatment of pneumonia
• Currently receiving or likely to receive any known inhibitors or inducers of cytochrome P450 mediated drug metabolism
• Immunocompromised subjects

Where it is running

• Enanta Pharmaceuticals, Inc. — Watertown, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.